Lexicon Pharmaceuticals, Inc.
As of Oct 22, 2026, Lexicon Pharmaceuticals is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $1.49, 43.6% below its 52-week high and below its 200-day average, which is rising.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LXRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LXRX among Biotechnology176th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …176 | LXRX | Stage 3 · wk 5 | 57 | −27.7% |
Lexicon Pharmaceuticals: quick answers
What stage is Lexicon Pharmaceuticals in?
As of Oct 22, 2026, Lexicon Pharmaceuticals (LXRX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean
Is Lexicon Pharmaceuticals in an uptrend?
Its uptrend has stalled. Lexicon Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 20.6% below its 200-day average, which is rising.
How far is Lexicon Pharmaceuticals from its 52-week high?
Lexicon Pharmaceuticals closed at $1.49 on Oct 22, 2026, 43.6% below its 52-week high of $2.64. Its 52-week low is $1.14.
How has Lexicon Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Lexicon Pharmaceuticals is up 3.5% over the past year and up 30.7% so far in 2026.
Which sector and industry is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.